clinical trials for glp-1 obesity meds actively recruiting GLP-1R agonists: Full of hope, use with caution Clinical Data Mega-Collection of Obesity

Sterile sucrose solutions at 3% were diluted with an equal volume of sterile L-DOPA solutions and prepared from a 5 mM stock in distilled water to obtain sugar solutions supplemented with L-DOPA at concentrations ranging from 0.2 to 10 mM (0.4 to 20% w/w) L-DOPA

Refrigeration after mixing is typically recommended to maintain optimal solution quality and extend usability

In addition, neither the stroke patient group nor the control group were treated with anti-diabetic drugs

Now, they have applications across many more specialties

For patients with heart failure or chronic kidney disease, SGLT2 inhibitors are generally preferred first, with GLP-1 agonists considered when SGLT2 inhibitors are contraindicated or not tolerated